An international multidisciplinary consensus statement on MAFLD and the risk of CVD

[1]  A. Allen,et al.  Challenges and opportunities in NASH drug development , 2023, Nature Medicine.

[2]  K. Sung,et al.  Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study , 2023, Arteriosclerosis, thrombosis, and vascular biology.

[3]  K. Sung,et al.  Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention , 2022, Cardiovascular Diabetology.

[4]  T. Naimi,et al.  Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Carlos D. Minacapelli,et al.  Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease , 2022, JAMA network open.

[6]  P. Zhang,et al.  The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China , 2022, Frontiers in Endocrinology.

[7]  C. Chen,et al.  Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis , 2022, Frontiers in Endocrinology.

[8]  Yingli Lu,et al.  Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China , 2022, Frontiers in Endocrinology.

[9]  Manjulika Das.  WHO urges immediate action to tackle non-communicable diseases. , 2022, The Lancet. Oncology.

[10]  D. Dombrowicz,et al.  High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation , 2022, Frontiers in Endocrinology.

[11]  H. Tilg,et al.  Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals , 2022, Gut.

[12]  Y. Dan,et al.  The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases , 2022, Frontiers in Genetics.

[13]  Dandan Peng,et al.  Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology , 2022, Frontiers in endocrinology.

[14]  Xin-Lei Zhang,et al.  Promoting the term MAFLD: China in action. , 2022, The lancet. Gastroenterology & hepatology.

[15]  A. Badr,et al.  Chrysin Attenuates Fructose-Induced Nonalcoholic Fatty Liver in Rats via Antioxidant and Anti-Inflammatory Effects: The Role of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis , 2022, Oxidative medicine and cellular longevity.

[16]  T. Kanai,et al.  A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis , 2022, PloS one.

[17]  J. I. Lee,et al.  MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups , 2022, Digestive Diseases and Sciences.

[18]  R. Zheng,et al.  New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study , 2022, Frontiers of Medicine.

[19]  M. Zheng,et al.  Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease , 2022, Diabetes & metabolism journal.

[20]  Sharan Jhaveri,et al.  Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease , 2022, Cureus.

[21]  E. Ferrannini,et al.  SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease , 2022, Trends in Endocrinology & Metabolism.

[22]  Sang-Man Jin,et al.  The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study , 2022, Cardiovascular Diabetology.

[23]  J. Reed,et al.  The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome , 2022, Journal of clinical medicine.

[24]  E. Kang,et al.  Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease , 2022, Gut and liver.

[25]  A. Sanyal,et al.  Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis , 2022, Hepatology International.

[26]  A. Sanyal,et al.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals , 2022, Clinical and molecular hepatology.

[27]  Mary E. Haas,et al.  Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease , 2022, JAMA network open.

[28]  V. Wong,et al.  Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[29]  B. Hanratty,et al.  Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis , 2022, BMJ Open.

[30]  J. Gumprecht,et al.  Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota , 2021, Nutrients.

[31]  V. Wong,et al.  ACE inhibitors prevent liver-related events in non-alcoholic fatty liver disease. , 2021, Hepatology.

[32]  S. Coldewey,et al.  The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease , 2021, Biomedicines.

[33]  P. Schauer,et al.  Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. , 2021, JAMA.

[34]  Myeong Jun Song,et al.  Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.

[35]  Arturo Santos,et al.  Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases , 2021, International journal of molecular sciences.

[36]  N. H. Cho,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease , 2021, Gut and liver.

[37]  M. Zheng,et al.  Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study , 2021, Hepatology International.

[38]  A. Nakajima,et al.  Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan , 2021, Journal of Gastroenterology.

[39]  A. Moeed,et al.  Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. , 2021, Clinics and research in hepatology and gastroenterology.

[40]  A. Sanyal,et al.  A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  C. Byrne,et al.  Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[42]  Y. Bao,et al.  Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China , 2021, The Journal of clinical endocrinology and metabolism.

[43]  Xianli Liu,et al.  Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis , 2021, The Journal of international medical research.

[44]  Donghee Kim,et al.  Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. , 2021, Journal of hepatology.

[45]  E. Bugianesi,et al.  Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[46]  H. Schunkert,et al.  Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies , 2021, JACC. Basic to translational science.

[47]  L. Ji,et al.  NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III , 2021, Frontiers in Medicine.

[48]  M. Kurosaki,et al.  Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease , 2021, Journal of gastroenterology and hepatology.

[49]  A. Farcomeni,et al.  Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis , 2021, British journal of clinical pharmacology.

[50]  T. Kawaguchi,et al.  MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[51]  Ningjian Wang,et al.  Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016 , 2021, Chinese medical journal.

[52]  M. Nguyen,et al.  Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  H. Tilg,et al.  Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. , 2021, The lancet. Gastroenterology & hepatology.

[54]  R. Zheng,et al.  The Progression and Regression of Metabolic Dysfunction-associated Fatty Liver Disease are Associated with the Development of Subclinical Atherosclerosis: A Prospective Analysis. , 2021, Metabolism: clinical and experimental.

[55]  Ajit S. Divakaruni,et al.  Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity , 2021, Hepatology communications.

[56]  E. Ingelsson,et al.  Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank , 2021, Digestive Diseases and Sciences.

[57]  W. Mai,et al.  Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[58]  A. Mantovani,et al.  Treatments for NAFLD: State of Art , 2021, International journal of molecular sciences.

[59]  B. Zhong,et al.  Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis , 2021, Lipids in health and disease.

[60]  A. Lonardo,et al.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials , 2021, Metabolites.

[61]  D. Niederseer,et al.  NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations , 2021, Journal of clinical medicine.

[62]  I. Bentov,et al.  Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?" , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[63]  D. Pastori,et al.  Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk? , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[64]  M. Petroni,et al.  Management of non-alcoholic fatty liver disease , 2021, BMJ.

[65]  M. Zheng,et al.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. , 2021, Hepatobiliary surgery and nutrition.

[66]  G. Targher,et al.  Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials , 2020, Metabolites.

[67]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[68]  M. Zheng,et al.  Clinical utility of the MAFLD definition. , 2020, Journal of hepatology.

[69]  Mai Mehrez,et al.  The NAFLD‐MAFLD debate: Eminence vs evidence , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[70]  M. Zheng,et al.  MAFLD and risk of CKD. , 2020, Metabolism: clinical and experimental.

[71]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[72]  I. Bentov,et al.  Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[73]  J. Woo,et al.  Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[74]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[75]  A. Kasturiratne,et al.  Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study , 2020, medRxiv.

[76]  M. del Ben,et al.  New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress , 2020, Nutrients.

[77]  A. Courcoulas,et al.  Benefits and Risks of Bariatric Surgery in Adults: A Review. , 2020, JAMA.

[78]  A. Scheen.  Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus , 2020, Nature Reviews Endocrinology.

[79]  S. Hazen,et al.  Gut Microbiota and Cardiovascular Disease , 2020, Circulation research.

[80]  T. Kanai,et al.  Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. , 2020, Alcohol.

[81]  Michael T. Lu,et al.  Association of Hepatic Steatosis with Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  V. Wong,et al.  From NAFLD to MAFLD: a “redefining” moment for fatty liver disease , 2020, Chinese medical journal.

[83]  F. Violi,et al.  Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease , 2020, Nutrients.

[84]  H. Tilg,et al.  From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.

[85]  S. Gilani,et al.  Diagnostic accuracy of carotid intima media thickness by B-mode ultrasonography in coronary artery disease patients , 2020, Archives of medical sciences. Atherosclerotic diseases.

[86]  N. Marx,et al.  [Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)]. , 2020, Deutsche medizinische Wochenschrift.

[87]  H. Tilg,et al.  NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.

[88]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[89]  K. Clément,et al.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders , 2020, Nature Reviews Gastroenterology & Hepatology.

[90]  C. Apovian,et al.  Joint international consensus statement for ending stigma of obesity , 2020, Nature Medicine.

[91]  A. de Gottardi,et al.  The gut-liver axis in liver disease: pathophysiological basis for therapy. , 2020, Journal of hepatology.

[92]  Hongliang Li,et al.  Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases , 2020, Circulation research.

[93]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[94]  E. Braunwald,et al.  Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[95]  E. Braunwald,et al.  Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[96]  V. Wong,et al.  Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease , 2020, Journal of gastroenterology and hepatology.

[97]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[98]  Haiming Hu,et al.  Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives , 2019, Journal of Gastroenterology.

[99]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[100]  A. Leite-Moreira,et al.  Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis , 2019, Endocrine.

[101]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[102]  Yan Liu,et al.  Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis , 2019, Scientific Reports.

[103]  R. Gish,et al.  Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. , 2019, Gastroenterology & hepatology.

[104]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[105]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[106]  F. Bäckhed,et al.  Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[107]  N. Chalasani,et al.  Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[108]  M. Karsdal,et al.  ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis , 2019, Hepatology.

[109]  G. Qin,et al.  Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[110]  A. Duseja,et al.  Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? , 2019, Journal of clinical and experimental hepatology.

[111]  Nik Raihan Nik Mustapha,et al.  Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus , 2019, Digestive Diseases and Sciences.

[112]  Yoosoo Chang,et al.  Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study , 2018, Hepatology.

[113]  C. Reinhardt.  The Gut Microbiota as an Influencing Factor of Arterial Thrombosis , 2018, Hämostaseologie.

[114]  K. Cusi,et al.  Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial , 2018, Journal of diabetes.

[115]  B. Neuschwander‐Tetri,et al.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[116]  Claudio Aguayo,et al.  Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.

[117]  M. Zheng,et al.  Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis , 2018, European journal of gastroenterology & hepatology.

[118]  K. Furie,et al.  Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone , 2018, Circulation.

[119]  D. Bennett,et al.  Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies , 2018, Diabetology International.

[120]  M. Friedrich-Rust,et al.  Patatin‐like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events , 2018, Hepatology communications.

[121]  H. Tilg,et al.  Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease , 2018, Nature Reviews Gastroenterology & Hepatology.

[122]  William J. Astle,et al.  Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies , 2018, The Lancet.

[123]  M. Zheng,et al.  Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta‐analysis , 2018, Hepatology communications.

[124]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[125]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[126]  C. Lewis,et al.  Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. , 2017, Gastroenterology.

[127]  F. Ceci,et al.  Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance , 2017, The American Journal of Gastroenterology.

[128]  Raquel S. Sevilla,et al.  Exome-wide association study of plasma lipids in >300,000 individuals , 2017, Nature Genetics.

[129]  N. Terrault,et al.  Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review , 2017, Hepatology.

[130]  S. Bakker,et al.  Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[131]  A. Isaacs,et al.  PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. , 2017, Gastroenterology.

[132]  K. Furie,et al.  Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus , 2017, Circulation.

[133]  Yingying Ding,et al.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.

[134]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[135]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[136]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[137]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[138]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[139]  Q. Anstee,et al.  The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 , 2015, Seminars in Liver Disease.

[140]  Puneet Puri,et al.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[141]  A. McCullough,et al.  Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[142]  Y. Kokubo,et al.  Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. , 2014, Journal of atherosclerosis and thrombosis.

[143]  You-Ming Li,et al.  Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. , 2014, World journal of gastroenterology.

[144]  A. Hofman,et al.  Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative , 2013, Diabetologia.

[145]  P. Paschos,et al.  Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. , 2012, World journal of hepatology.

[146]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[147]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[148]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[149]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[150]  G. Alexander,et al.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease , 2010, Gut.

[151]  B. Pannier,et al.  Relationship between alcohol intake, health and social status and cardiovascular risk factors in the urban Paris-Ile-De-France Cohort: is the cardioprotective action of alcohol a myth? , 2010, European Journal of Clinical Nutrition.

[152]  S. Costanzo,et al.  Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. , 2010, Journal of the American College of Cardiology.

[153]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[154]  G. Mensah,et al.  Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. , 2005, American journal of preventive medicine.

[155]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.